The pharmaceutical industry wants to rethink menopause as a business... and medicate more
The pharmaceutical industry wants to rethink menopause as a business... and medicate more
"Previously, menopause was a source of shame. Now it is an advantage in a rapidly growing market, valued at more than $10 billion, with little traditional competition for a segment of underdiagnosed and undertreated consumers."
"Philanthropy and private capital are betting that research and development of menopause products represent the next wave of the future of female consumption."
0 respuestas
0 favoritos
0 impulsos